Key result
Alamandine treatment for 14 days attenuated the development of fibrosis, reduced respiratory system elastance, and preserved weight gain in a rat model of bleomycin-induced pulmonary fibrosis.
Why the study?
Pulmonary fibrosis has limited treatment options, and reduced alamandine levels in idiopathic pulmonary fibrosis suggest it may be a therapeutic target.
Does alamandine alleviate pulmonary fibrosis and improve respiratory mechanics in a bleomycin-induced rat model?
Does alamandine alleviate pulmonary fibrosis and improve respiratory mechanics in a bleomycin-induced rat model?
Alamandine shows potential as an antifibrotic therapy by alleviating pulmonary fibrosis and improving respiratory mechanics in a preclinical rodent model.
Answers are grounded in this paper and cite their sources.
Should not yet inform clinical management of pulmonary fibrosis; extends preclinical evidence and warrants human trials.
Introduction. Pulmonary fibrosis (PF) is characterized by an accelerated decline in pulmonary function and has limited treatment options. Alamandine (ALA) is a recently described protective peptide of the renin-angiotensin system (RAS) with essential tasks in several conditions. Our group previously demonstrated that ALA is reduced by 365% in the plasma of patients with idiopathic PF, and thus, it is plausible to believe that stimulation of this peptide could represent an important therapeutic target. In this sense, this study investigates the effects of ALA in an experimental model of PF. Materials and Methods. Bleomycin (BLM) was administrated in Wistar rats, and these fibrotic animals were treated with ALA for 14 days. Body weight, histology, respiratory, and hemodynamic parameters were analyzed to study the effects of ALA. Results. ALA treatment attenuated the development of fibrosis ([Formula: see text]), reduced respiratory system elastance ([Formula: see text]), and preserved weight gain ([Formula: see text]) in fibrotic animals without affecting the autonomic control of blood pressure and heart rate. Conclusion. The data from this study demonstrate the potential of ALA to alleviate pulmonary fibrosis and improve respiratory system mechanics in vivo. The promising results encourage more detailed investigations of the potential of ALA as a future and efficient antifibrotic.
No takes yet. Share an insight, caveat, or question.
Fernandes et al. (2021) studied Pulmonary fibrosis. Alamandine (ALA) vs. Untreated fibrotic animals was evaluated on Development of fibrosis, respiratory system elastance, and weight gain. Alamandine treatment for 14 days attenuated the development of fibrosis, reduced respiratory system elastance, and preserved weight gain in a rat model of bleomycin-induced pulmonary fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: